International review of neurobiology
2025
Stephan Tap, Tijmen Bostoen, Joost J. Breeksema et al.
4 citations
Patients with a life-threatening disease (LTD) sometimes suffer from end-of-life distress (EOLD) which refers to the physical, psychological, emotional, and spiritual suffering related to chronic illness and the possibility of death. Palliative care interventions seek to improve the quality of life of patients with EOLD and their significant others. Currently, a range of psychological and...
medRxiv
2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
3 citations
preprint
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and...
Frontiers in Psychiatry
2025
Justin Dwyer, Robert B. Johnston, Clare O'Callaghan et al.
5 citations
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychedelic experience in a predictable way that has been codified into music recommendations and playlists. To re-evaluate the nature and role of music within the participant's world during psychedelic-assisted psychotherapy. Phenomenological analysis of...
Current Topics in Behavioral Neurosciences
December 31, 2024
Mazdak M. Bradberry, Paul S. Appelbaum, Natalie Gukasyan
7 citations
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in...
Journal of Eating Disorders
December 27, 2024
Elena Koning, Cristiano Chaves, Elisa Brietzke et al.
2 citations
Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dysfunction, directly affecting 1-3% of the population. Standard treatments are not effective in approximately one third of ED cases, representing the need for scientific advancement. There is emerging evidence for the safety and efficacy of...
Australian & New Zealand Journal of Psychiatry
December 13, 2024
Rosana Freitas, Efstathia Stephanie Gotsis, Alexander T. Gallo et al.
14 citations
Introduction: Psilocybin, a classical psychedelic, has been rescheduled for use in psilocybin-assisted psychotherapy for treatment-resistant depression in Australia. While evidence for its use is promising, understanding the associated risks is crucial. Accordingly, this review aims to collate adverse event data from psilocybin-assisted psychotherapy clinical trials and evaluate its definition,...
Frontiers in Psychiatry
December 6, 2024
Jonathan Brett, Elizabeth Knock, Kathy Watson et al.
7 citations
Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin,...
CNS Spectrums
December 1, 2024
Mathieu Fradet, Carlton M Kelly, Anna Donnelly et al.
10 citations
Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summarizes the most recent data on its safety and efficacy. The delivery of psilocybin therapy and its subjective effects are also presented. Furthermore, this chapter outlines our current understanding of psilocybin's pharmacology and neurobiological effects....
Psychedelic Medicine
November 18, 2024
Shakila Meshkat, Erica Kaczmarek, Zoe Doyle et al.
8 citations
Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown promise for its rapid-acting antidepressant effects, though its impact on bipolar depression remains unexplored. In the present subgroup analysis of an already published trial on treatment-resistant depression (TRD), we aimed to preliminarily evaluate...
Scientific Reports
November 14, 2024
Erin Wang, David S. Mathai, Natalie Gukasyan et al.
18 citations
Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA has shown promise for conditions including depression and post-traumatic stress disorder. Psilocybin and MDMA may become approved medicines in the coming decade. This study assessed knowledge and attitudes regarding PAT among 879 U.S. healthcare professionals via anonymous online survey. Multivariable linear regression...